Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Background We used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma antigens, B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor.Methods The APRIL CAR was evaluated in a Phase 1 clinic...

Full description

Bibliographic Details
Main Authors: Simon Thomas, Julia Taylor, Manuel Rodriguez-Justo, Kwee Yong, Mathieu Ferrari, Shimobi Onuoha, Sonja Zweegman, Rakesh Popat, Lydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, Kent Fung, Dominic Patel, Zulaikha Akbar, Elena Alvarez Mediavilla, Patrycja Wawrzyniecka, Debarati Shome, Rogier M Reijmers, Trillian Gregg, Leigh Wood, William Day, Virginie Cerec, Shaun Cordoba, Nushmia Khokhar, Vijay Peddareddigari, Muhammad Al-Hajj, Jim Cavet, Martin Pule
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/6/e006699.full

Internet

https://jitc.bmj.com/content/11/6/e006699.full

Similar Items